Panel firm offers speedy trend analysis

Share this article:
All Global, a Kantar-owned provider of healthcare panel data, has launched a service designed to offer, within 24 hours, analyzed responses to breaking drug news.
The service, Snapshot, can generate sample sizes in the hundreds across six countries, according to a release. For example, within hours of the FDA's decision to severely restrict use of GlaxoSmithKline diabetes pill Avandia, Snapshot closed a survey of 100 UK diabetes specialists and endocrinologists, with 63% saying the news would encourage their use of a DPP 4 inhibitor/GLP 1 mimetic, 12% saying they would initiate insulin earlier, and 13% saying they would not change Rx habits.
Release of FDA ad-com briefing documents for weight-loss candidate Qnexa prompted a Snapshot survey of 730 US PCPs, with 82% saying they would recommend approval. In a follow-up survey of 398 PCPs after the ad-com voted 10-6 against approval, 68% said they would have recommended approval.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.

Email Newsletters